12TH ANNUAL SCIENTIFIC SYMPOSIUM A CME/CNE - Certified Conference

BRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer

Keynote Speaker and Basser Global Prize Awardee: Kenneth Offit, MD, MPH

MONDAY, MAY 13 – TUESDAY, MAY 14, 2024

Smilow Center for Translational Research Auditorium/Commons (enter through Perelman Center for Advanced Medicine)



Program Overview

This hybrid symposium is designed to educate researchers, scientists, and health care providers in cancer genetics by presenting cutting-edge data from renowned researchers and clinicians. This symposium will provide new information on progress in cancer screening and prevention, as well as ongoing work in targeted therapy for BRCA1/2 and other mutation carriers through a series of lectures and panel discussions.

PROGRAM OBJECTIVES

At the completion of this symposium, attendees should be able to:

- Discuss new research on the genetic epidemiology of *BRCA1/2* and other homologous recombination deficiency (HRD) genes.
- Describe current ethical, legal and social issues associated with carrying a *BRCA1/2* mutation.
- Review new approaches to screening and prevention of hereditary breast, ovarian, pancreatic and prostate cancer.
- Discuss new advances in treatment for mutation carriers of *BRCA1/2* and other known cancer susceptibility genes.

WHO SHOULD ATTEND

Healthcare providers including medical oncology, surgical oncology, gynecology oncology, OB-GYN, genetic counselors, primary care physicians, physician assistants and nurses/nurse practitioners who are interested in the genetics of *BRCA1/2* related cancers.

The symposium is sponsored in part by a generous gift from Margaret I. Cuomo and Howard Maier.



KEYNOTE SPEAKER AND BASSER GLOBAL PRIZE AWARDEE Kenneth Offit, MD, MPH

Chief, Clinical Genetics Service Memorial Sloan Kettering Cancer Center

The Basser Center is honored to announce Kenneth Offit, MD, MPH of Memorial Sloan Kettering Cancer Center, is the recipient of the

12th annual Basser Global Prize. Dr. Offit is the Robert and Kate Niehaus Chair in Inherited Cancer Genomics and serves as Chief of the Clinical Genetics Service at MSKCC. Dr. Offit received his MD and MPH from Harvard University. Dr. Offit's work identified the most common mutation associated with an increased risk of breast, ovarian, and prostate cancer among individuals of Ashkenazi Jewish ancestry He also published the first prospective series describing the outcome of preventive ovarian surgery and screening in women at hereditary risk for breast and ovarian cancer.

Dr. Offit founded one of the first clinical cancer genetics services in 1992 and led the first American Society of Clinical Oncology policy statement after the identification of the BRCA1 and BRCA2 genes. His ongoing research includes leading an implementation study, funded by the National Institutes of Health, to pilot health dissemination of genomic information.



SYMPOSIUM CHAIR Susan M. Domchek, MD

Executive Director, Basser Center for BRCA Director, Mariann and Robert MacDonald Cancer Risk Evaluation Center

Susan Domchek is the Basser Professor in Oncology at the Perelman School of Medicine of the University of Pennsylvania. She serves as

Executive Director of the Basser Center for BRCA at the Abramson Cancer Center and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Center. Her work focuses on the genetic evaluation and medical management of individuals with inherited risk factors for cancer. Dr. Domchek is particularly interested in developing new cancer therapies, such as PARP inhibitors, for patients with genetic risk factors. An elected member of the National Academy of Medicine, Dr. Domchek is also a significant contributor to the oncology literature. She has authored/co-authored more than 400 articles appearing in scholarly journals including the New England Journal of Medicine, the Journal of the American Medical Association and the Journal of Clinical Oncology, among others.

SYMPOSIUM CO-ORGANIZERS Ronald Drapkin, MD, PhD

Franklin Payne Associate Professor of Pathology in Obstetrics & Gynecology Director, Penn Ovarian Cancer Research Center Director of Gynecologic Cancer Research, Basser Center for BRCA

Dana Farengo Clark, MS, MS, LCGC

Senior Genetic Counselor Mariann & Robert MacDonald Cancer Risk Evaluation Center Basser Center for BRCA

Adam Fredo, PA-C

Physician Assistant Medical Oncology Penn Medicine

Roger Greenberg, MD, PhD

J. Samuel Staub, MD, Professor, Department of Cancer Biology Director, Penn Center for Genome Integrity (PCGI) Director of Basic Science, Basser Center for BRCA

Mosetta Harris, CRNP

Nurse Practitioner Rena Rowan Breast Center Penn Medicine

Katherine Nathanson, MD

Pearl Basser Professor of BRCA-Related Research Deputy Director, Abramson Cancer Center Director of Genetics, Basser Center for BRCA

PENN MEDICINE FACULTY Jessica Ebrahimzadeh, MS, LCGC

Genetic Counselor Mariann & Robert MacDonald Cancer Risk Evaluation Center Basser Center for BRCA

Derek Mann, MS, LCGC

Genetic Counselor Mariann & Robert MacDonald Cancer Risk Evaluation Center Basser Center for BRCA

Ben Stanger, MD, PhD

Hanna Wise Professor in Cancer Research Director, Penn Pancreatic Cancer Research Center

GUEST SPEAKERS Samuel Bakhoum, MD, PhD

Associate Attending Radiation Oncologist Memorial Sloan Kettering Cancer Center

Jennifer Guerriero, PhD

Assistant Professor, Harvard Medical School Lead Investigator, Brigham and Women's Hospital Breast Cancer Program, Dana-Farber/Harvard Cancer Center Harvard Immunology, Harvard Medical School

Jada Hamilton, PhD, MPH

Co-Director, Genomics, Risk & Health Decision-Making Laboratory Associate Attending Psychologist, Department of Psychiatry & Behavioral Sciences Clinical Genetics Service, Department of Medicine Memorial Sloan Kettering Cancer Center

Kai Kessenbrock, PhD

Associate Professor, Biological Chemistry Chao Family Comprehensive Cancer Center University of California, Irvine

Hendrik Messal, PhD

Senior Postdoctoral Researcher The Netherlands Cancer Institute

Kenneth Olive, PhD

Associate Professor of Medicine Columbia University Irving Medical Center

John Richardson

Director of Policy and Government Affairs National Society of Genetic Counselors (NSGC)

Mark Robson, MD

Chief, Breast Medicine Service Clinic Director, Clinical Genetics Service Memorial Sloan Kettering Cancer Center

Sven Rottenberg, DVM, PhD, Dipl. ECVP

Department Chair, Department of Infectious Diseases and Pathobiology (DIP), Vetsuisse Faculty, University of Bern

Violeta Serra, PhD

Group Leader, Experimental Therapeutics Group Miguel Servet Investigator Vall D'Hebron Institute of Oncology, Barcelona Spain

Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH

Professor of Translational Cancer Genetics | Institute of Cancer Research NHS Consultant in Clinical Cancer Genetics (Honorary) | Royal Marsden NHS Foundation Trust Consultant in Public Health Medicine (Honorary)| Public Health England

Laura Valle, PhD

Principal Investigator Hereditary Cancer Program Catalan Institute of Oncology, IDIBELL Barcelona, Spain

Gilbert Welch, MD, MPH

Center for Surgery and Public Health Brigham and Women's Hospital

Gerburg Wulf, MD, PhD

Associate Professor of Medicine, Harvard Medical School Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center

Dmitriy Zamarin, MD, PhD

Associate Professor Section Head, Gynecologic Medical Oncology Precision Immunology Institute Icahn School of Medicine at Mount Sinai Dana Farber/Harvard Cancer Center

$12^{\text{TH}} \text{ANNUAL SCIENTIFIC SYMPOSIUM} \\ AGENDA$

MONDAY, MAY 13, 2024

| 7:30-8:15am | Registration |
|-----------------|---|
| 8:15-8:30am | Welcome |
| | |
| Morning Session | |
| 8:30-9:00am | Kai Kessenbrock, PhD |
| | Understanding the role of the microenvironment in <i>BRCA1</i> -driven breast tumorigenesis |
| 9:00-9:30am | Samuel Bakhoum, MD, PhD |
| | Chromosomal instability as a source of tumor-promoting inflammation |
| 9:30-10:00am | Kenneth Olive, PhD Targeting and preventing pancreatic cancer BRCA2-mutant mouse models |
| | |
| 10:00-10:30am | BREAK |
| 10:30-11:00am | Jennifer Guerriero, PhD |
| | Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in <i>BRCA1</i> -associated triple-negative breast cancer |
| 11:00-11:30am | Hendrik Messal, PhD |
| | |

A high burden of abnormal cell behavior in disease-free human breasts 11:30-12:00pm Roger Greenberg, MD, PhD Targeting homologous recombination deficient cancers

12:00-1:15pm

LUNCH

12^{TH} annual scientific symposium AGENDA

MONDAY, MAY 13, 2024

Afternoon Session

| 1:15-1:45pm | Ben Stanger, MD, PhD Personalized models and interception strategies for pancreatic cancer |
|-------------|---|
| 1:45-2:15pm | Dmitriy Zamarin, MD, PhD Overcoming immune heterogeneity in ovarian cancer |
| 2:15-2:45pm | Violeta Serra, PhD HRD beyond <i>BRCA1/2</i> and the need of functional biomarkers |
| 2:45-3:15pm | Sven Rottenberg, DVM, PhD, Dipl. ECVP Mechanisms of genetic reversion-independent chemoresistance in BRCA1/2-mutated tumors |
| 3:15-3:45pm | Gerburg Wulf, MD, PhD A short course of olaparib combinations for the prevention of BRCA1-realted breast cancer |
| | End of accredited portion |

4:00-5:00pm Poster Session

$12^{\text{TH}} \text{ANNUAL SCIENTIFIC SYMPOSIUM} \\ AGENDA$

TUESDAY, MAY 14, 2024

| 7:30-8:15am | Registration |
|-----------------|--|
| 8:15-8:30am | Welcome |
| Morning Session | |
| 8:30-9:00am | Gilbert Welch, MD Multicancer early detection screening: Challenges posed by birds, rabbits, and turtles |
| 9:00-9:30am | Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH Population genomic risk stratification to inform cancer screening |
| 9:30-10:00am | Mark Robson, MD Update on treatment of hereditary breast cancer |
| | |
| 10:00-10:30am | BREAK |
| 10:30-11:00am | Laura Valle, PhD APC 11307K and cancer risk: Recommendations of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT) for classification of the variant, cancer screening, and predictive testing |
| 11:00-11:30am | Katherine Nathanson, MD Comprehensive analysis of the landscape of reversion mutations in HR genes |
| 11:30-12:00pm | Jada Hamilton, PhD, MPH Implications of polygenic risk scores for risk-reducing mastectomy decision-making experiences among <i>BRCA1/2</i> carriers |
| 12:00-1:15pm | LUNCH |

12^{TH} annual scientific symposium AGENDA

TUESDAY, MAY 14, 2024

Afternoon Session

| 1:15-1:45pm | John Richardson Genetic Counselor advocacy update: State licensure and Medicare provider status |
|-------------|---|
| 1:45-2:15pm | Derek Mann, MS, LCGC Year in review: Updates and trends in hereditary cancer genetic counseling |
| 2:15-3:00pm | Case Panel moderated by Susan Domchek, MD with: |
| | Jessica Ebrahimzadeh MS, LCGC, Kenneth Offit, MD, MPH and Mark Robson, MD |
| | |
| 3:00-3:15pm | BREAK |
| 3:15-4:30pm | Global Prize Presentation and Keynote |
| | Kenneth Offit, MD, MPH BRCA at 30: Phenotype, penetrance and populations |
| 4:30-5:00pm | Wrap Up and Evaluations |
| | End of accredited portion |
| 5:00-6:30pm | Breakthroughs & Discoveries Panel moderated by Jill Werman Harris: featuring Susan Domchek, MD, Kenneth Offit, MD, MPH, Gilbert Welch, MD, Clare Turnbull, MD, PhD, FRCP, FRCPath, MFPH |
| | This lay session is open to the public. |

Registration Information

REGISTER ONLINE

This conference is **FREE** but we strongly recommend registration. Registration is required for continuing education credits.

ACCREDITATION AND DESIGNATION OF CREDIT

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Nurse/Nurse Practitioners

The program will award 12.5 NCPD hours

Physicians

Penn Medicine designates this live activity for a maximum of 12.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Physician Assistants

AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credits™* from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 12.5 Category 1 credits for completing this activity.

Genetic Counselors

This event has been submitted to the National Society of Genetic Counselors (NSGC) for approval of Category 1 CEUs. The American Board of Genetic Counseling (ABGC) accepts CEUs approved by NSGC for purposes of recertification. Approval for the requested CEUs and Contact Hours is currently pending.

CANCELLATION POLICY

The University reserves the right to cancel or postpone any activity due to unforeseen circumstances. In the event of cancellation or postponement, the University will not be responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines, or travel agencies.

SERVICES FOR THE DISABLED

If special arrangements are required for an individual with a disability to attend this meeting, please contact <u>basserinfo@pennmedicine.upenn.edu</u> by April 29, 2024.

SPECIAL REQUESTS


If special requests for food or other logistics are required, contact <u>basserinfo@pennmedicine.upenn.edu</u> by April 29, 2024.

NONDISCRIMINATION STATEMENT

The University of Pennsylvania values diversity and seeks talented students, faculty and staff from diverse backgrounds. The University of Pennsylvania does not discriminate on the basis of race, sex, sexual orientation, gender identity, religion, color, national or ethnic origin, age, disability, or status as a Vietnam Era Veteran or disabled veteran in the administration of educational policies, programs or activities; admissions policies; scholarship and loan awards; athletic, or other University administered programs or employment. Questions or complaints regarding this policy should be directed to: Executive Director, Office of Affirmative Action and Equal Opportunity Programs, 3600 Chestnut Street, Sansom Place East, Suite 228, Philadelphia, PA 19104-6106 or 215.898.6993 (Voice) or 215.898.7803 (TDD).

Visiting Information

PENN MEDICINE CAMPUS MAP



HOTEL

A block of rooms has been reserved at the Sheraton Philadelphia University City Hotel at a special group rate of \$199 per night.

Rooms must be reserved by April 13, 2024 to take advantage of the group rate.

RESERVE YOUR ROOM

For more information, contact Basserinfo@pennmedicine.upenn.edu or call 215.662.4348

COVID GUIDELINES

Penn Medicine's COVID guidelines for visitors to campus can be found here: <u>https://www.pennmedicine.org/coronavirus/visitation-policy-and-guidelines</u>

PARKING


Parking will not be available on the medical campus, but public self-pay parking lots available in the University City vicinity can be found at:

- Drexel University Parking Lot 34th and Market Streets
- University of Pennylvania Parking Lot 34th and Chestnut Streets
- University of Pennsylvania Parking Lot 38th and Walnut Streets

For more information, visit <u>http://cms.business-services.upenn.edu/parking/</u>

PUBLIC TRANSPORTATION

The SEPTA Penn Medicine Station (formerly University City Station) is within walking distance of the medical campus. For more information, visit <u>www.septa.org</u>.



For more information, contact Basserinfo@pennmedicine.upenn.edu or call 215.662.4348

The Basser Center for BRCA is the first comprehensive center for the research, treatment and prevention of BRCA-related cancers. Devoted to advancing care for people affected by BRCA mutations, the Basser Center's unique model provides funding for collaborative research, education and outreach programs around the world.

WE TAKE CANCER PERSONALLY.



